Urokinase Market Report 2026

The urokinase market size has grown strongly in recent years. It will grow from $1.81 billion in 2025 to $1.91 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to increasing incidence of cardiovascular and thrombotic disorders, reliance on traditional clot dissolution therapies, growing hospital admissions for acute myocardial infarction, limited availability of alternative thrombolytic agents, expansion of clinical use in catheter management.

The urokinase market size is expected to see strong growth in the next few years. It will grow to $2.38 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to advancements in biotechnological manufacturing methods, rising adoption of recombinant urokinase, growth in minimally invasive vascular procedures, increasing awareness of early thrombolytic intervention, expanding healthcare infrastructure in emerging markets. Major trends in the forecast period include increasing use of thrombolytic therapies for acute cardiovascular conditions, rising adoption of recombinant and biotechnologically produced urokinase, growing demand for catheter clearance and minimally invasive procedures, expansion of hospital-based thrombolytic treatment protocols, improved formulations and ready-to-use urokinase solutions.

The increasing burden of cardiovascular diseases is expected to drive the growth of the urokinase market in the coming years. Cardiovascular diseases (CVDs) encompass a broad range of conditions that affect the heart and blood vessels, including heart attacks, strokes, and hypertension. The rising prevalence of cardiovascular diseases is largely attributed to factors such as increasing obesity rates linked to physical inactivity, unhealthy dietary patterns, and an aging population. Urokinase plays an important role in reducing the impact of cardiovascular diseases by dissolving blood clots that obstruct blood flow, helping to prevent heart attacks and strokes, restore normal circulation, and reduce the risk of further cardiovascular complications. For example, in October 2024, according to the Centers for Disease Control and Prevention, a US-based federal agency, cardiovascular disease accounted for 919,032 deaths in 2023, representing nearly one in every three deaths. As a result, the growing burden of cardiovascular diseases is contributing to the expansion of the urokinase market.

Major companies operating in the urokinase market are focusing on reintroducing and commercializing pharmaceutical products for new indications to improve treatment effectiveness, strengthen market positioning, and expand patient access. The reintroduction and commercialization of a drug for new indications involves bringing an existing or previously discontinued product back to the market for additional therapeutic uses, supported by marketing, distribution, and sales strategies. For instance, in May 2023, MBX Biosciences, a US-based biopharmaceutical company, partnered with Sequel Pharma LLC, a US-based pharmaceutical company, to reintroduce and commercialize Kinlytic urokinase. This initiative is intended to expand its footprint in the catheter clearance market and improve patient treatment outcomes. The partnership reflects a broader industry trend of using strategic collaborations to successfully relaunch pharmaceutical products in alignment with current market demands and regulatory requirements.

In August 2023, Eli Lilly and Company, a US-based pharmaceutical company, acquired DICE Therapeutics Inc. for $48 billion. This acquisition is designed to strengthen Eli Lilly’s research and development capabilities in innovative therapies, potentially supporting advances in thrombolytic treatments and related therapeutic areas, including those that may complement urokinase-based therapies. DICE Therapeutics Inc. is a US-based biotechnology company specializing in the discovery and development of novel treatments for autoimmune and inflammatory diseases.

Major companies operating in the urokinase market are Thermo Fisher Scientific Inc., Mochida Pharmaceutical Co. Ltd., Bharat Serums and Vaccines Limited, Taj Pharmaceuticals Ltd., TTK Health Care Limited, Agrata Biotech Limited, Cerbios-Pharma SA, Microbix Biosystems Inc., Midas Pharma GmbH, ImaRx Therapeutics, Health Biotech Limited, Salvavidas Pharmaceutical Pvt. Ltd., BBT Biotech GmbH, Syner-Med (Pharmaceutical Products) Ltd., Echelon Biosciences Inc., Kraeber & Co GmbH, Samarth Life Science Pvt. Ltd., WUHAN HANWEISHI PHARMCHEM CO. LTD., Aetos Pharma, MITS CRITICAL CARE.

North America was the largest region in the urokinase market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the urokinase market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the urokinase market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the urokinase market by increasing the cost of imported biotechnological raw materials, enzymes, and pharmaceutical manufacturing inputs, leading to higher production and treatment costs. Hospital pharmacies and injectable urokinase solutions are particularly affected, especially in regions such as Asia-Pacific and Europe that depend on cross-border supply chains. These challenges have caused pricing pressures and supply adjustments. However, tariffs have also encouraged domestic biopharmaceutical manufacturing and investments in local production capabilities, supporting long-term market stability and innovation.

The urokinase market research report is one of a series of new reports that provides urokinase market statistics, including urokinase industry global market size, regional shares, competitors with a urokinase market share, detailed urokinase market segments, market trends and opportunities, and any further data you may need to thrive in the urokinase industry. This urokinase market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Urokinase is a therapeutic enzyme that functions as a thrombolytic agent for dissolving blood clots. It works by converting plasminogen into plasmin, which subsequently breaks down fibrin, the main structural protein of blood clots. Urokinase is used in clinical settings to treat conditions such as acute myocardial infarction and other clot-related disorders by restoring blood flow and lowering the risk of serious complications caused by thrombosis.

The primary types of urokinase include urokinase powder and urokinase solution. Urokinase powder is the dry, powdered form of the thrombolytic drug, which is usually reconstituted with sterile water or saline prior to administration, offering advantages in storage, transportation, and dose preparation compared with liquid forms. Manufacturing processes include biotechnological methods as well as traditional extraction techniques. Urokinase is used for several indications such as catheter clearance, coronary artery thrombosis, deep vein thrombosis, and pulmonary embolism. It is distributed through various channels including hospital pharmacies, retail pharmacies, and online pharmacies, and is used across applications such as hospitals, clinics, and others.

The urokinase market consists of sales of urokinase thrombolytic agents, urokinase enzymes, and urokinase injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.